Page last updated: 2024-08-26

sr141716 and Anxiety Neuroses

sr141716 has been researched along with Anxiety Neuroses in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (55.56)	29.6817
2010's	4 (44.44)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bowers, ME; Ressler, KJ	1
Grieb, M; Lutz, B; Moreira, FA	1
Crippa, JA; Moreira, FA	1
Cravatt, BF; Kinsey, SG; Lichtman, AH; Long, JZ; O'Neal, ST	1
Browning, M; Cowen, PJ; Di Simplicio, M; Harmer, CJ; Horder, J	1
Bagdy, G; Gonda, X; Kirilly, E	1
Bortolato, M; Calignano, A; Campolongo, P; Cuomo, V; Frau, R; Gessa, GL; La Rana, G; Mangieri, RA; Piomelli, D; Russo, R; Scattoni, ML; Trezza, V	1
González-Cuevas, G; López-Moreno, JA; Navarro, M	1
Astrup, A; Bartels, EM; Bliddal, H; Christensen, R; Kristensen, PK	1

Reviews

4 review(s) available for sr141716 and Anxiety Neuroses

Article	Year
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:1 Topics: Affect; Animals; Anxiety Disorders; Cannabinoid Receptor Modulators; Depressive Disorder; Dronabinol; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2009
The psychiatric side-effects of rimonabant. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2009, Volume: 31, Issue:2 Topics: Anxiety Disorders; Appetite Depressants; Cannabinoid Receptor Modulators; Depressive Disorder; Humans; Metabolic Diseases; Obesity; Piperidines; Placebo Effect; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Smoking; Smoking Cessation	2009
CB1 receptor antagonists: new discoveries leading to new perspectives. Acta physiologica (Oxford, England), 2012, Volume: 205, Issue:1 Topics: Anti-Obesity Agents; Anxiety Disorders; Depressive Disorder; Humans; Obesity; Piperidines; Precision Medicine; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2012
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600 Topics: Anti-Obesity Agents; Anxiety Disorders; Depression; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss	2007

Trials

1 trial(s) available for sr141716 and Anxiety Neuroses

Article	Year
Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:1 Topics: Adult; Anxiety Disorders; Depression; Emotions; Female; Humans; Male; Memory, Short-Term; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Recognition, Psychology; Rimonabant; Young Adult	2012

Other Studies

4 other study(ies) available for sr141716 and Anxiety Neuroses

Article	Year
Sex-dependence of anxiety-like behavior in cannabinoid receptor 1 (Cnr1) knockout mice. Behavioural brain research, 2016, Mar-01, Volume: 300 Topics: Animals; Anxiety Disorders; Cannabinoid Receptor Antagonists; Exploratory Behavior; Female; Male; Mice, Inbred C57BL; Mice, Knockout; Ovariectomy; Piperidines; Psychotropic Drugs; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sex Characteristics	2016
Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacology, biochemistry, and behavior, 2011, Volume: 98, Issue:1 Topics: Amidohydrolases; Animals; Anti-Anxiety Agents; Anxiety Disorders; Benzodioxoles; Cannabinoid Receptor Modulators; Diazepam; Disease Models, Animal; Dronabinol; Endocannabinoids; Enzyme Inhibitors; Male; Mice; Mice, Inbred C57BL; Monoacylglycerol Lipases; Obsessive-Compulsive Disorder; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2011
Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2006, Volume: 31, Issue:12 Topics: Animals; Animals, Newborn; Anti-Anxiety Agents; Anxiety Disorders; Anxiety, Separation; Arachidonic Acids; Behavior, Animal; Brain; Cannabinoid Receptor Modulators; Carrier Proteins; Disease Models, Animal; Endocannabinoids; Male; Maze Learning; Neural Inhibition; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Cannabinoid, CB1; Reflex, Startle; Rimonabant	2006
The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol. Neurobiology of disease, 2007, Volume: 25, Issue:2 Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Anxiety Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Synergism; Male; Maze Learning; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Reinforcement, Psychology; Rimonabant; Secondary Prevention; Substance Withdrawal Syndrome; Sucrose	2007